In short, the expression of TMEM16A can predict the efficacy of EGFR/HER2 inhibitors in BC and HNSCC patients and monitor the recurrence situation, and can be used as a biomarker to predict the efficacy of imatinib in treating GIST patients. The gene discussed is ANO1; the disease is head and neck squamous cell carcinoma.